Streetbeat News

Regulatory

BCDA

BioCardia has received CMS approval for coverage of its CardiAMP Cell Therapy Phase III study in heart failure, potentially accelerating patient enrollment and advancing the therapy's development.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:04 am

ADM

Archer-Daniels-Midland (ADM) announced a correction of historical financial information for specific segments and a plan to remediate material weaknesses. This move aims to enhance financial transparency and accuracy.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:03 am

KALV

KalVista Pharmaceuticals has received the Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency for Sebetralstat, a treatment for Hereditary Angioedema.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:38 am

ADM

Archer-Daniels-Midland (ADM) disclosed a material weakness in its internal control over financial reporting, attributing it to inadequate controls that permitted the reporting of certain intersegment sales at values not close to market rates.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:24 am

ADM

Archer-Daniels-Midland (ADM) announced that following its January 21, 2024, announcement of an investigation, it has received voluntary document requests from the Department of Justice (DoJ), primarily focused on the same subject matter.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:21 am

GOOG

MSFT

The ongoing feud between Mark Cuban and Elon Musk extends to AI bias discussions, with Musk criticizing AI models like OpenAI's GPT-4 and Google's Gemini for bias, while Cuban argues that no AI can be bias-free and market preferences will dictate AI development. Musk has also been promoting his own AI, xAI's Grok, as unbiased. The debate includes concerns over AI content moderation filters and calls for open-sourcing AI technologies.

Portfolio Pulse from Rounak Jain

March 12, 2024 | 9:10 am

BEKE

FXI

Chinese regulators have requested large banks to increase their support for Vanke, a major real estate company in China. This move is part of broader efforts to stabilize the real estate sector in the country.

Portfolio Pulse from Charles Gross

March 12, 2024 | 9:08 am

FXI

Chinese Premier Li Qiang will not meet with foreign CEOs at the China Development Forum in late March, signaling potential challenges for international business relations.

Portfolio Pulse from Charles Gross

March 12, 2024 | 8:54 am

NXTP

NextPlay Technologies, Inc. (NXTP) received a notice from NASDAQ for not holding an annual meeting of shareholders within the stipulated period, violating NASDAQ's Listing Rules. This non-compliance serves as an additional basis for the potential delisting of the Company's securities from The Nasdaq Stock Market.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 7:29 am

CALT

Calliditas Therapeutics (CALT) announced that the U.S. FDA has granted a seven-year orphan drug exclusivity for Nefecon, expiring in December 2030, for a new indication to reduce kidney function loss in adults with primary IgAN.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 7:15 am